When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALXN - Fortress Bio and Alexion launch late-stage CAEL-101 study in AL amyloidosis
Alexion Pharmaceuticals Inc.
Fortress Biotech (NASDAQ:FBIO)announces that Caelum Biosciences in collaboration with Alexion Pharmaceuticals (NASDAQ:ALXN) have initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, an amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in AL amyloidosis, a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow that leads to heart and kidney damage.
More news on: Fortress Biotech, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news,